- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Patient Advocates Demand Oral Parity in North Carolina
The demand for oral parity for oncology medications is back up for vote in the Senate in North Carolina.
Patient advocacy groups in North Carolina, like ACSCAN, are demanding that the state should implement the oral/infusion cancer drug parity law. While Oregon was the first state to pass the law in 2008, 39 states and the District of Columbia have followed suit. Today, North Carolina is one of 11 states where insurers demand higher out-of-pocket costs from patients on oral anticancer agents, compared with those who get infusions or injections.
“It should not matter what method of chemotherapy a cancer patient is receiving, whether it’s an IV infusion or a pill,” said Christine Weason, the North Carolina government relations director for the American Cancer Society Cancer Action Network in an interview. “It’s just about fairness.” A bill to this effect, passed in the North Carolina House in April this year, is currently pending in the Senate.
Read more in The Charlotte Observer.
Watch a panel discussion among payers and healthcare policy experts on the topic that was recently convened by AJMC.
Read more here: http://www.charlotteobserver.com/living/health-family/article27365617.html#storylink=cpy
Sarcoma Care: Biomarker Advancements Shape the Future
October 24th 2024At the regional Institute for Value-Based Medicine® event in Boston, Vinayak Venkataraman, MD, medical oncologist at Dana-Farber Cancer Institute and Harvard Medical School, was a panelist for the discussion, “Recent Advancements in Identifying Predictive Biomarkers for Sarcomas."
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Prediagnosis Diet Improves Survival in Black Women With Deadly Ovarian Cancer
October 24th 2024Moderate prediagnosis adherence to dietary guidelines was associated with improved survival rates among Black women with high-grade serous ovarian cancer, the most common and lethal type of ovarian cancer.
Read More
Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value
July 18th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.
Listen
Rozanolixizumab Effective in Patients with MuSK MG, Analysis Shows
October 23rd 2024A new subgroup analysis of patients with muscle-specific tyrosine kinase (MuSK) autoantibody-positive (Ab+) myasthenia gravis (MG) shows rozanolixizumab (Rystiggo) contributes to meaningful symptom improvement.
Read More
